BACKGROUND: The incidence of esophageal cancer has risen among all age groups. Controversy exists about the clinical presentation and prognosis of young patients. The aim of this study was to compare the clinicopathologic characteristics and outcomes after surgery between patients with esophageal cancer who were <50 years of age and those ≥50 years of age. METHODS: Patients diagnosed with esophageal carcinoma who underwent esophagectomy between January 1990 and December 2010 in a single institution were selected from a prospective database. Patients aged <50 years at diagnosis (n = 163) were compared with those ≥50 years (n = 1151) with respect to clinicopathologic stage and oncologic outcome. RESULTS: Younger patients had less co-morbidity (p < 0.001). There were no significantly differences in tumor localization, histology, differentiation, or TNM stage in the two groups. In both groups, 37 % of the patients underwent neoadjuvant chemo(radio)therapy. One or more nonsurgical complications developed in 53 % of the older group versus 42 % in the younger group (p = 0.012). In-hospital mortality was 6.3 % for patients ≥50 years compared to 1.8 % for younger patients (p = 0.021). The 5 year overall survival was significantly better for the younger patients than for those ≥50 years (41 vs. 31 %, p < 0.001), but median disease-specific and disease-free survival did not differ between the groups (37 vs. 30 months, p = 0.140 and 49 vs. 28 months, p = 0.079, respectively). Multivariate analysis identified moderate, poorly, and undifferentiated tumors; tumor-positive resection margins (pR1-2); and TNM stage IIB-IV as independent predictors of disease-specific survival. CONCLUSIONS: A considerable proportion (12 %) of patients diagnosed with resectable esophageal carcinoma were <50 years. Phenotypic tumor characteristics and disease-specific survival were comparable for the two age groups.
BACKGROUND: The incidence of esophageal cancer has risen among all age groups. Controversy exists about the clinical presentation and prognosis of young patients. The aim of this study was to compare the clinicopathologic characteristics and outcomes after surgery between patients with esophageal cancer who were <50 years of age and those ≥50 years of age. METHODS:Patients diagnosed with esophageal carcinoma who underwent esophagectomy between January 1990 and December 2010 in a single institution were selected from a prospective database. Patients aged <50 years at diagnosis (n = 163) were compared with those ≥50 years (n = 1151) with respect to clinicopathologic stage and oncologic outcome. RESULTS: Younger patients had less co-morbidity (p < 0.001). There were no significantly differences in tumor localization, histology, differentiation, or TNM stage in the two groups. In both groups, 37 % of the patients underwent neoadjuvant chemo(radio)therapy. One or more nonsurgical complications developed in 53 % of the older group versus 42 % in the younger group (p = 0.012). In-hospital mortality was 6.3 % for patients ≥50 years compared to 1.8 % for younger patients (p = 0.021). The 5 year overall survival was significantly better for the younger patients than for those ≥50 years (41 vs. 31 %, p < 0.001), but median disease-specific and disease-free survival did not differ between the groups (37 vs. 30 months, p = 0.140 and 49 vs. 28 months, p = 0.079, respectively). Multivariate analysis identified moderate, poorly, and undifferentiated tumors; tumor-positive resection margins (pR1-2); and TNM stage IIB-IV as independent predictors of disease-specific survival. CONCLUSIONS: A considerable proportion (12 %) of patients diagnosed with resectable esophageal carcinoma were <50 years. Phenotypic tumor characteristics and disease-specific survival were comparable for the two age groups.
Authors: Catherine M Olsen; Nirmala Pandeya; Adèle C Green; Penelope M Webb; David C Whiteman Journal: Am J Epidemiol Date: 2011-06-30 Impact factor: 4.897
Authors: Cristina Bosetti; Fabio Levi; Jacques Ferlay; Werner Garavello; Franca Lucchini; Paola Bertuccio; Eva Negri; Carlo La Vecchia Journal: Int J Cancer Date: 2008-03-01 Impact factor: 7.396
Authors: J J Boonstra; L B Koppert; B P Wijnhoven; H W Tilanus; H Van Dekken; T C K Tran; A Van der Gaast Journal: J Surg Oncol Date: 2009-10-01 Impact factor: 3.454
Authors: D C Whiteman; S Sadeghi; N Pandeya; B M Smithers; D C Gotley; C J Bain; P M Webb; A C Green Journal: Gut Date: 2007-10-11 Impact factor: 23.059
Authors: Jurjen J Boonstra; Tjebbe C Kok; Bas Pl Wijnhoven; Mark van Heijl; Mark I van Berge Henegouwen; Fiebo Jw Ten Kate; Peter D Siersema; Winand Nm Dinjens; Jan Jb van Lanschot; Hugo W Tilanus; Ate van der Gaast Journal: BMC Cancer Date: 2011-05-19 Impact factor: 4.430
Authors: M van Heijl; J J B van Lanschot; L B Koppert; M I van Berge Henegouwen; K Muller; E W Steyerberg; H van Dekken; B P L Wijnhoven; H W Tilanus; D J Richel; O R C Busch; J F Bartelsman; C C E Koning; G J Offerhaus; A van der Gaast Journal: BMC Surg Date: 2008-11-26 Impact factor: 2.102